Please tell me some thing's about Ewing's sarcoma on last stage.What can I do for help child who have a this problem.He get a morfium for pain.What is with "hidrazin sulfat"drug?
THIS IS THE LAST CHANCE,PLEASE TELL ME HOW CAN I GET MORE INFORMATION FOR THIS:
Scientists unveil molecule that disrupts Ewing's sarcoma oncogene
Monday 14th April, 2008
Washington, April 14 : American scientists have identified a small molecule that may be helpful in inactivating a gene that causes Ewing's sarcoma, a rare cancer found in children and young adults.
The breakthrough results form the efforts of scientists at Georgetown University Medical Center, who say that further studies may establish the novel agent as the first targeted therapy to treat Ewing's sarcoma, wherein tumours can occur anywhere in the body.
Making a presentation at the annual meeting of the American Association for Cancer Research (AACR) in San Diego, the researchers revealed that the activity of the molecule was based on a protein-protein interaction.
They further said that their findings suggested that the same interaction could provide a model upon which other therapies could be designed.
"I think this holds really wonderful promise as a unique way of targeting fusion proteins. People thought it wasn't possible to have a small molecule that can bind between flexible proteins, but we have shown that it can be done," said lead researcher Dr. Jeffrey Toretsky, a pediatric oncology physician and researcher at Georgetown University's Lombardi Comprehensive Cancer Center.
Toretsky conceded that more research was required before the novel agent could be tested in humans, as laboratory cells were used for the study. He revealed that further lab studies were underway.
Ewing's sarcoma results from the exchange of DNA between two chromosomes, a process known as a translocation. The new gene, EWS-FLI1, is created when the EWS gene on chromosome 22 fuses to the FLI1 gene on chromosome 11, and its product is the fusion protein responsible for cancer formation.
Toretsky and his laboratory colleagues are the first to make a recombinant EWS-FLI1 fusion protein.
"We did this in order to find out if EWS-FLI1 might be binding with other cellular proteins," he says.
The researchers observed that the fusion protein actually stuck to another protein known as RNA helicase A (RHA), a molecule that forms protein complexes in order to control gene transcription.
"We believe that when RHA binds to EWS-FLI1, the combination becomes more powerful at turning genes on and off," says the study's first author, Dr. Hayriye Verda Erkizan, a postdoctoral researcher in Toretsky's lab who is presenting the study results at AACR.
Using a lab method of keeping RHA apart from the fusion protein revealed that both were important to cancer formation, and thereafter the researchers decided to explore molecules that could keep the two proteins separated.
The researchers used a library of small molecules loaned to Georgetown from the National Cancer Institute, and tested 3,000 compounds. They found that one of them could very tightly bind to immobilized EWS-FLI1 proteins.
Erkizan said that the discovery was wonderful because scientists had always thought that it was not possible to block protein-protein interactions, as the surface of the proteins are slippery and much too flexible for a drug to bind to.
"These are wiggly proteins yet this study shows that inhibition of protein-protein interactions with a small molecule is possible," Toretsky says.
This possibility means that fusion proteins, such as those produced in other sarcomas as well as diverse disorders, might be inhibited, he says.
Ewing's sarcoma is a malignant round-cell tumor. It is a rare disease in which cancer cells are found in the bone or in soft tissue. The most common areas in which it occurs are the pelvis, the femur, the humerus, and the ribs.
Ewing's sarcoma occurs most frequently in male teenagers.Ewing's sarcoma is the result of a translocation between chromosomes 11 and 22, which fuses the EWS gene of chromosome 22 to the FLI1 gene of chromosome 11.
Ewing's sarcoma is more common in males and usually presents in childhood or early adulthood, with a peak between 10 and 20 years of age. It can occur anywhere in the body, but most commonly in the pelvis and proximal long tubular bones. The diaphyses of the femur are the most common sites, followed by the tibia and the humerus.
Because almost all patients with apparently localized disease at diagnosis have occult metastatic disease, multidrug chemotherapy (often including ifosfamide and etoposide) as well as local disease control with surgery and/or radiation is indicated in the treatment of all patients.
Treatment often consists of neo-adjuvant chemotherapy generally followed by wide or radical excision, and may also include radiotherapy. Complete excision at the time of biopsy may be performed if malignancy is confirmed at that time.
Treatment lengths vary depending on location and stage of the disease at diagnosis. Radical chemotherapy may be as short as 6 treatments at 3 week cycles, however most patients will undergo chemotherapy for 6-12 months and radiation therapy for 5-8 weeks.
Hydrazine sulfate is a chemical compound that has been studied as a treatment for cancer and certain side effects caused by cancer.Hydrazine sulfate is sold as a dietary supplement in the United States. The US Food and Drug Administration has not approved the use of hydrazine sulfate as a cancer treatment, except in clinical trials.
The article you have qouted suggests the possibility of an option, not an established treatment for the cancer.
Regards and God bless.
This site complies with the HONcode standard for trustworthy health information.
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.